These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 35499461

  • 1. Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors.
    Tomar S, Zhang J, Khanal M, Hong J, Venugopalan A, Jiang Q, Sengupta M, Miettinen M, Li N, Pastan I, Ho M, Hassan R.
    Mol Cancer Ther; 2022 Jul 05; 21(7):1195-1206. PubMed ID: 35499461
    [Abstract] [Full Text] [Related]

  • 2. Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity.
    Chu GJ, Bailey CG, Nagarajah R, Liang O, Metierre C, Sagnella SM, Castelletti L, Yeo D, Adelstein S, Rasko JEJ.
    Cytotherapy; 2024 Apr 05; 26(4):325-333. PubMed ID: 38349311
    [Abstract] [Full Text] [Related]

  • 3. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
    Hung CF, Xu X, Li L, Ma Y, Jin Q, Viley A, Allen C, Natarajan P, Shivakumar R, Peshwa MV, Emens LA.
    Hum Gene Ther; 2018 May 05; 29(5):614-625. PubMed ID: 29334771
    [Abstract] [Full Text] [Related]

  • 4. Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope.
    Liu XF, Onda M, Schlomer J, Bassel L, Kozlov S, Tai CH, Zhou Q, Liu W, Tsao HE, Hassan R, Ho M, Pastan I.
    Proc Natl Acad Sci U S A; 2024 Jan 23; 121(4):e2317283121. PubMed ID: 38227666
    [Abstract] [Full Text] [Related]

  • 5. Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects.
    Zhu Y, Wang K, Yue L, Zuo D, Sheng J, Lan S, Zhao Z, Dong S, Hu S, Chen X, Feng M.
    Pharmacol Res; 2024 May 23; 203():107186. PubMed ID: 38641176
    [Abstract] [Full Text] [Related]

  • 6. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
    Wehrli M, Guinn S, Birocchi F, Kuo A, Sun Y, Larson RC, Almazan AJ, Scarfò I, Bouffard AA, Bailey SR, Anekal PV, Montero Llopis P, Nieman LT, Song Y, Xu KH, Berger TR, Kann MC, Leick MB, Silva H, Salas-Benito D, Kienka T, Grauwet K, Armstrong TD, Zhang R, Zhu Q, Fu J, Schmidts A, Korell F, Jan M, Choi BD, Liss AS, Boland GM, Ting DT, Burkhart RA, Jenkins RW, Zheng L, Jaffee EM, Zimmerman JW, Maus MV.
    Clin Cancer Res; 2024 May 01; 30(9):1859-1877. PubMed ID: 38393682
    [Abstract] [Full Text] [Related]

  • 7. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
    Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M.
    Sci Transl Med; 2014 Nov 05; 6(261):261ra151. PubMed ID: 25378643
    [Abstract] [Full Text] [Related]

  • 8. Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer.
    Zhu Y, Zuo D, Wang K, Lan S, He H, Chen L, Chen X, Feng M.
    J Cancer Res Clin Oncol; 2023 Nov 05; 149(16):15027-15038. PubMed ID: 37612388
    [Abstract] [Full Text] [Related]

  • 9. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.
    Cao B, Liu M, Wang L, Liang B, Feng Y, Chen X, Shi Y, Zhang J, Ye X, Tian Y, Zhi C, Li J, Lian H, Wu Q, Zhang Z.
    Biochem Biophys Res Commun; 2020 Mar 26; 524(1):96-102. PubMed ID: 31980173
    [Abstract] [Full Text] [Related]

  • 10. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
    Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, Beatty GL.
    Mol Ther; 2019 Nov 06; 27(11):1919-1929. PubMed ID: 31420241
    [Abstract] [Full Text] [Related]

  • 11. Ligand-based adoptive T cell targeting CA125 in ovarian cancer.
    Zhao H, Wu L, Dai J, Sun K, Zi Z, Guan J, Zhang L.
    J Transl Med; 2023 Sep 05; 21(1):596. PubMed ID: 37670338
    [Abstract] [Full Text] [Related]

  • 12. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
    Wang Y, Wang J, Yang X, Yang J, Lu P, Zhao L, Li B, Pan H, Jiang Z, Shen X, Liang Z, Liang Y, Zhu H.
    Front Immunol; 2021 Sep 05; 12():628906. PubMed ID: 33777013
    [Abstract] [Full Text] [Related]

  • 13. Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor.
    Zhang Z, Jiang D, Yang H, He Z, Liu X, Qin W, Li L, Wang C, Li Y, Li H, Xu H, Jin H, Qian Q.
    Cell Death Dis; 2019 Jun 17; 10(7):476. PubMed ID: 31209210
    [Abstract] [Full Text] [Related]

  • 14. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
    Liu G, Zhang Q, Liu G, Li D, Zhang L, Gu Z, Tian H, Zhang Y, Tian X.
    Exp Cell Res; 2021 Dec 01; 409(1):112886. PubMed ID: 34673000
    [Abstract] [Full Text] [Related]

  • 15. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.
    Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, Powell DJ.
    Mol Ther; 2012 Mar 01; 20(3):633-43. PubMed ID: 22127019
    [Abstract] [Full Text] [Related]

  • 16. Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer.
    Amit U, Uslu U, Verginadis II, Kim MM, Motlagh SAO, Diffenderfer ES, Assenmacher CA, Bicher S, Atoche SJ, Ben-Josef E, Young RM, June CH, Koumenis C.
    Proc Natl Acad Sci U S A; 2024 Jul 30; 121(31):e2403002121. PubMed ID: 39047033
    [Abstract] [Full Text] [Related]

  • 17. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, Keith B, Young RM, Engels B, Sorsa S, Siurala M, Havunen R, Tähtinen S, Hemminki A, June CH.
    JCI Insight; 2018 Apr 05; 3(7):. PubMed ID: 29618658
    [Abstract] [Full Text] [Related]

  • 18. Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer.
    Li K, Xu J, Wang J, Lu C, Dai Y, Dai Q, Zhang W, Xu C, Wu S, Kang Y.
    Cancer Immunol Immunother; 2023 Apr 05; 72(4):917-928. PubMed ID: 36166071
    [Abstract] [Full Text] [Related]

  • 19. Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model.
    Soltantoyeh T, Akbari B, Shahosseini Z, Mirzaei HR, Hadjati J.
    Front Immunol; 2024 Apr 05; 15():1362904. PubMed ID: 38855110
    [Abstract] [Full Text] [Related]

  • 20. Development of a CD39 nanobody and its enhancement to chimeric antigen receptor T cells efficacy against ovarian cancer in preclinical studies.
    Zhang YC, Li XY, Deng Q, Ge YJ, Yi RR, Wang HJ, Wang JT, Zhou H, Kong XF, Liu RJ, Zhang YT, Li XP, He XW, Zhu HY.
    Theranostics; 2024 Apr 05; 14(16):6249-6267. PubMed ID: 39431011
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.